De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

NeuroOne Medical Technologies Toekomstige groei

Future criteriumcontroles 0/6

Momenteel beschikken we niet over voldoende analisten om de groei en omzet voor NeuroOne Medical Technologies te voorspellen.

Belangrijke informatie

n/a

Groei van de winst

n/a

Groei van de winst per aandeel

Medical Equipment winstgroei	17.6%
Inkomstengroei	n/a
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	None
Laatst bijgewerkt	n/a

Recente toekomstige groei-updates

Recent updates

Is NeuroOne Medical Technologies (NASDAQ:NMTC) In A Good Position To Deliver On Growth Plans?

Dec 16

Can NeuroOne Medical Technologies (NASDAQ:NMTC) Afford To Invest In Growth?

Jul 25

Here's Why We're Watching NeuroOne Medical Technologies' (NASDAQ:NMTC) Cash Burn Situation

Apr 11

We Think NeuroOne Medical Technologies (NASDAQ:NMTC) Needs To Drive Business Growth Carefully

Sep 15

NeuroOne rallies on receiving $3.5M in accelerated milestone payment from Zimmer Biomet

Aug 03

Is NeuroOne Medical Technologies (NASDAQ:NMTC) In A Good Position To Deliver On Growth Plans?

Jun 02

Companies Like NeuroOne Medical Technologies (NASDAQ:NMTC) Could Be Quite Risky

Dec 18

NeuroOne: Thin Film Electrodes For Diagnosis And Treatment Of Neurological Conditions

Nov 19

Will NeuroOne Medical Technologies (NASDAQ:NMTC) Spend Its Cash Wisely?

Sep 04

We're Not Very Worried About NeuroOne Medical Technologies' (NASDAQ:NMTC) Cash Burn Rate

May 27

In dit gedeelte presenteren we gewoonlijk prognoses voor de omzet- en winstgroei op basis van de consensusramingen van professionele analisten om beleggers te helpen begrijpen in hoeverre het bedrijf in staat is winst te genereren. Maar omdat NeuroOne Medical Technologies onvoldoende gegevens uit het verleden heeft verstrekt en geen analistenprognose heeft, kan de toekomstige winst niet betrouwbaar worden berekend door gegevens uit het verleden te extrapoleren of analistenprognoses te gebruiken.

Dit is een vrij zeldzame situatie, aangezien 97% van de bedrijven die worden gedekt door SimplyWall St wel financiële gegevens uit het verleden hebben.

Winst- en omzetgroeiprognoses

NasdaqCM:NMTC - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
6/30/2024	4	-12	-11	-11	N/A
3/31/2024	4	-13	-12	-12	N/A
12/31/2023	3	-13	-14	-13	N/A
9/30/2023	3	-12	-13	-13	N/A
6/30/2023	5	-10	-9	-9	N/A
3/31/2023	4	-9	-9	-9	N/A
12/31/2022	4	-9	-9	-8	N/A
9/30/2022	2	-10	-8	-8	N/A
6/30/2022	0	-11	-11	-11	N/A
3/31/2022	0	-11	-10	-10	N/A
12/31/2021	0	-11	-10	-9	N/A
9/30/2021	0	-10	-9	-9	N/A
6/30/2021	2	-8	-6	-6	N/A
3/31/2021	2	-12	-5	-5	N/A
12/31/2020	2	-11	-4	-4	N/A
9/30/2020	2	-14	-4	-3	N/A
6/30/2020	N/A	-14	-5	-5	N/A
3/31/2020	N/A	-9	-5	-5	N/A
12/31/2019	N/A	-10	-6	-6	N/A
9/30/2019	N/A	-7	-6	-5	N/A
6/30/2019	N/A	-8	-5	-5	N/A
3/31/2019	N/A	-7	-4	-4	N/A
12/31/2018	N/A	-6	-3	-3	N/A
9/30/2018	N/A	-7	-3	-3	N/A
6/30/2018	N/A	-6	-3	-2	N/A
3/31/2018	N/A	-6	N/A	-2	N/A
12/31/2017	N/A	-5	N/A	-2	N/A
9/30/2017	N/A	-4	N/A	-2	N/A
3/31/2017	N/A	-1	N/A	-1	N/A
12/31/2016	N/A	0	N/A	0	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: Er zijn onvoldoende gegevens om te bepalen of de verwachte winstgroei van NMTC boven de spaarquote ( 2.5% ) ligt.

Winst versus markt: Er zijn onvoldoende gegevens om te bepalen of de winst van NMTC naar verwachting sneller zal groeien dan de markt US

Hoge groeiwinsten: Er zijn onvoldoende gegevens om te bepalen of de winst van NMTC naar verwachting de komende 3 jaar aanzienlijk zal groeien.

Omzet versus markt: Er zijn onvoldoende gegevens om te bepalen of de omzet van NMTC naar verwachting sneller zal groeien dan de markt US.

Hoge groei-inkomsten: Er zijn onvoldoende gegevens om te bepalen of de omzet van NMTC naar verwachting sneller zal groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van NMTC naar verwachting over 3 jaar hoog zal zijn

NeuroOne Medical Technologies Toekomstige groei

Future criteriumcontroles 0/6

Belangrijke informatie

Recente toekomstige groei-updates

Price target decreased by 25% to US$2.00

Consensus revenue estimates decrease by 12%, EPS upgraded

Price target increased by 27% to US$2.67

Consensus revenue estimates increase by 13%, EPS downgraded

Consensus revenue estimates increase by 13%

Consensus revenue estimates decrease by 41%, EPS upgraded

Recent updates

Third quarter 2024 earnings released: US$0.10 loss per share (vs US$0.20 loss in 3Q 2023)

NeuroOne Medical Technologies Corporation to Report Q3, 2024 Results on Aug 14, 2024

NeuroOne Medical Technologies Corporation announced that it has received $2.650001 million in funding

NeuroOne Medical Technologies Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price Requirement

NeuroOne Medical Technologies Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price Requirement

Insufficient new directors

NeuroOne® Announces First in Human Ablations Completed with OneRF™ Ablation System

Neuroone Medical Technologies Corporation Receives Approval of ICD-10 Procedure Code for sEEG RF Ablation

Second quarter 2024 earnings released: US$0.11 loss per share (vs US$0.21 loss in 2Q 2023)

NeuroOne Medical Technologies Corporation to Report Q2, 2024 Results on May 14, 2024

Price target decreased by 25% to US$2.00

NeuroOne Medical Technologies Corporation Initiates Limited Commercial Launch of OneRF Ablation System

First quarter 2024 earnings: EPS in line with analyst expectations despite revenue beat

NeuroOne Medical Technologies Corporation to Report Q1, 2024 Results on Feb 13, 2024

NeuroOne Medical Technologies Corporation, Annual General Meeting, Mar 14, 2024

Chief Operating Officer recently bought US$105k worth of stock

Co-Founder notifies of intention to sell stock

Consensus revenue estimates decrease by 12%, EPS upgraded

Price target increased by 27% to US$2.67

Is NeuroOne Medical Technologies (NASDAQ:NMTC) In A Good Position To Deliver On Growth Plans?

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

NeuroOne Medical Technologies Corporation Receives FDA 510(K) Clearance to Market its OneRF(TM) Ablation System

NeuroOne Medical Technologies Corporation to Report Q4, 2023 Results on Dec 14, 2023

NeuroOne Medical Technologies Corporation Announces Patent Allowance for Drug Delivery Utilizing a Novel Neural Probe

NeuroOne Medical Technologies Corporation Appoints Christopher R. Volker as Chief Operating Officer

NeuroOne Medical Technologies Corporation Provides Progress Update on FDA 510(k) Submission for OneRF™? Ablation System

Chief Financial Officer recently bought US$50k worth of stock

Consensus revenue estimates increase by 13%, EPS downgraded

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

NeuroOne Medical Technologies Corporation to Report Q3, 2023 Results on Aug 14, 2023

New major risk - Share price stability

Can NeuroOne Medical Technologies (NASDAQ:NMTC) Afford To Invest In Growth?

NeuroOne Medical Technologies Corporation Submits 510(K) Application to FDA for OneRF™ Ablation System

NeuroOne Medical Technologies Corporation Announces First Clinical Case Using Evo® sEEG Electrode in Robotic Neurosurgery

Consensus revenue estimates increase by 13%

Second quarter 2023 earnings released: US$0.21 loss per share (vs US$0.19 loss in 2Q 2022)

NeuroOne Medical Technologies Corporation to Report Q2, 2023 Results on May 11, 2023

Here's Why We're Watching NeuroOne Medical Technologies' (NASDAQ:NMTC) Cash Burn Situation

Consensus revenue estimates decrease by 41%, EPS upgraded

First quarter 2023 earnings: EPS in line with expectations, revenues disappoint

NeuroOne Medical Technologies Corporation to Report Q1, 2023 Results on Feb 14, 2023

NeuroOne Medical Technologies Corporation, Annual General Meeting, Mar 16, 2023

Consensus revenue estimates increase by 154%

NeuroOne Medical Technologies Corporation Auditor Raises 'Going Concern' Doubt

Full year 2022 earnings: EPS and revenues exceed analyst expectations

NeuroOne Successfully Completes Feasibility Study with its OneRF Ablation System

Price target decreased to US$2.63

NeuroOne Medical Technologies Corporation Receives U.S. Food and Drug Administration 510(K) Clearance to Market Its Evo sEEG System for Less Than 30 Day Use

We Think NeuroOne Medical Technologies (NASDAQ:NMTC) Needs To Drive Business Growth Carefully

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

NeuroOne Medical Technologies Corporation Submits Special 510(k) to FDA for Evo sEEG Electrode

Consensus estimates of losses per share improve by 13%

NeuroOne rallies on receiving $3.5M in accelerated milestone payment from Zimmer Biomet

NeuroOne Announces First Clinical Case Using Evo sEEG Electrode

Is NeuroOne Medical Technologies (NASDAQ:NMTC) In A Good Position To Deliver On Growth Plans?

NeuroOne Medical Technologies Corporation Provides Evo's EEG Update

Second quarter 2022 earnings released: US$0.19 loss per share (vs US$0.21 loss in 2Q 2021)

NeuroOne Medical Technologies Corporation to Report Q2, 2022 Results on May 12, 2022

NeuroOne Medical Technologies Corporation, Annual General Meeting, May 31, 2022

Price target decreased to US$2.63

NeuroOne Medical Technologies Corporation Releases Successful Completion of Long-Term Stimulation Tests for Its Novel Thin Film Platform Electrode Technology

First quarter 2022 earnings: EPS misses analyst expectations

NeuroOne® Medical Technologies Corporation Releases Successful Long-Term Recording Test Data for Its Novel Thin Film Platform Electrode Technology

Companies Like NeuroOne Medical Technologies (NASDAQ:NMTC) Could Be Quite Risky

NeuroOne: Thin Film Electrodes For Diagnosis And Treatment Of Neurological Conditions

NeuroOne® Medical Technologies Corporation Announces Successful Completion of Feasibility Study for Ablation Electrode

NeuroOne Medical Technologies Corporation Receives FDA 510(k) Clearance for its Evo sEEG Electrode

Will NeuroOne Medical Technologies (NASDAQ:NMTC) Spend Its Cash Wisely?

Insider recently sold US$80k worth of stock